Lorcaserin and Renal dysfunction
Result of checking the interaction of drug Lorcaserin and disease Renal dysfunction for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Lorcaserin is extensively metabolized in the liver by multiple enzymatic pathways, and the metabolites are primarily eliminated by the kidney. In patients with varying degrees of renal function, lorcaserin systemic exposure (AUC) was not significantly different, but AUC of the sulfamate metabolite (M1) was increased by approximately 1.7-fold in mild (CrCl 50 to 80 mL/min), 2.3-fold in moderate (CrCl 30 to 50 mL/min), and 10.5-fold in severe renal impairment (CrCl <30 mL/min) compared to normal renal function (CrCl >80 mL/min), while AUC of the N-carbamoyl-glucuronide metabolite (M5) was increased by approximately 1.5-, 2.5-, and 5.1-fold, respectively. No dosage adjustment of lorcaserin is required in patients with mild renal impairment, but caution is advised when used in patients with moderate renal impairment. Use in patients with severe renal impairment or end stage renal disease is not recommended.
Generic Name: lorcaserin
Brand Name: Belviq, Belviq XR
Synonyms: n.a.